<dd id="yfl9j"><noscript id="yfl9j"></noscript></dd>

    <rp id="yfl9j"><acronym id="yfl9j"></acronym></rp><progress id="yfl9j"><pre id="yfl9j"></pre></progress>
      <rp id="yfl9j"></rp>
            1. <rp id="yfl9j"><acronym id="yfl9j"></acronym></rp>

                  1. <rp id="yfl9j"><object id="yfl9j"><input id="yfl9j"></input></object></rp>
                      <button id="yfl9j"></button><button id="yfl9j"><acronym id="yfl9j"></acronym></button>
                    1. <tbody id="yfl9j"></tbody>
                    2. <tbody id="yfl9j"></tbody>
                      <em id="yfl9j"><acronym id="yfl9j"></acronym></em>

                    3. Artificial heart valves and transcather implantation systems
                      The product which is interventive, minimally invasive, without surgical sutures and cardiopulmonary bypass is used to replace the diseased mitral valve. This new designed product can simplify the replacement surgery, significantly reducing the risks of treatment and increasing success rate. Moreover, this can shorten patients’ postoperative recovery time and cut down costs. Furthermore, reduced price of similar products enables more patients to have opportunities to endure risk and expense of surgery and treatment. As a revolutionary treatment, transcatheter artificial heart valve prosthesis is being well recognized by experts. In the future, clinical demands will grow explosively.
                      人工心臟瓣膜及導管植入系統具有介入、無手術縫線、無需體外循環和無須開胸手術等特點,用于置換心臟內病變的二尖瓣瓣膜。 這種新型產品將使心臟瓣膜置換手術過程簡化、治療風險大幅降低、成功率將顯著提高,同時也將縮短病人術后恢復時間及大大降低費用,拉低進口同類產品價格,使更多的病人能夠承受手術的風險和費用而得到治療。 介入人工心臟瓣膜作為一種革命性的治療手段,正日益被專家所認同,在可預見的未來幾年內,臨床需求將會呈現爆發性的增長。
                      无遮挡很爽很污很黄的网站 一女被多男玩喷潮视频| 成都4片p完整免费观看| 天天做天天爱天天综合网| 99精品视频九九精品视频| 久久99国产综合精品女同| 丰满的人妻bd高清| 欧美a级毛欧美1级a大片式放| 亚洲成a人片在线观看无码| 少妇高潮太爽了在线观看免费| 男女18禁啪啪无遮挡激烈| 国产精品亚洲а∨天堂123|